Previous 10 | Next 10 |
2023-09-17 12:00:54 ET The impact of COVID, flu, and RSV on U.S. and U.K. hospitals is expected to be lower this winter compared to last, as there won't be a significant overlap between peak outbreaks of infections, the London-based data analytics firm Airfinity said in a recent report. ...
2023-09-17 08:35:00 ET Summary Shanghai Hasten Biopharma has entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Insilico Medicine has out-licensed global rights to a small molecule inhibitor to Exelixis for BRCA-mutated tumors. ...
2023-09-14 16:56:27 ET More on Moderna, Pfizer, etc. Moderna wins EU recommendation for updated COVID shot Barclays projects over $5B COVID booster sales in fall 2023 Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans Moderna sees $10B – $15B...
2023-09-14 09:07:26 ET (24/7 MARKET NEWS) – First Wave BioPharma, Inc. (NASDAQ:FWBI) stated, this morning, that it signed an agreement to license Sanofi’s (NASDAQ:SNY) selective 5-HT4 receptor partial agonist, Capeserod, which First Wave will repurpose and develop for gastroin...
2023-09-14 07:45:00 ET Innovation never sleeps in the healthcare sector. At the beginning of this year, there had never been a vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of the respiratory syncytial virus (RSV). Now, three companies have managed to ea...
2023-09-14 06:46:02 ET More on Sanofi Sanofi: A 'Buy' Recommendation For Undervalued Growth Potential Sanofi ( SNY ) Q2 2023 Earnings Call Transcript Sanofi 2023 Q2 - Results - Earnings Call Presentation Sanofi: Powering Up And Offering Investors A Lot Of...
BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) dis...
2023-09-09 08:26:31 ET Summary Alnylam has an upcoming FDA advisory committee meeting on the company's application for Onpattro in ATTR-CM, and I see some risk of a negative committee vote. Onpattro has met or exceeded the efficacy targets established with the FDA, but I expect th...
2023-09-07 21:05:27 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-09-06 08:12:04 ET Summary Protalix BioTherapeutics reported Q2 2023 revenues of $35.08 million, a 300.72% YoY increase, beating Wall Street estimates. The US FDA approved PLX's Elfabrio for the treatment of Fabry disease in adults, expanding its commercialization target. ...
News, Short Squeeze, Breakout and More Instantly...
Sanofi ships U.S. influenza vaccines for the 2024/25 season PR Newswire Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
2024-07-09 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...